The most recent advances in bladder cancer treatment

Bladder cancer treatment has shifted significantly in the past five years, with three major changes reshaping how doctors approach the disease. Immunotherapy — drugs that help your immune system recognize and attack cancer cells — now plays a central role for many patients, especially those with advanced disease. Checkpoint inhibitors like atezolizumab, nivolumab, and pembrolizumab have become standard options when traditional chemotherapy alone is not enough or when surgery is not possible. For early-stage disease, a newer approach called BCG plus interferon combination therapy has shown better results than BCG alone in some patients, though BCG (Bacillus Calmette-Guérin) remains the first-line treatment for non-muscle-invasive bladder cancer.

The other major shift is in how doctors decide who needs surgery. Trimodal therapy — a combination of chemotherapy, radiation, and sometimes targeted drugs — now offers a bladder-sparing alternative to radical cystectomy (surgical removal of the bladder) for selected patients with muscle-invasive disease. This approach preserves bladder function while achieving comparable survival rates in carefully chosen cases, though it requires close monitoring and may not work for everyone.

Key Takeaways

  • Immunotherapy drugs (checkpoint inhibitors) are now standard treatment for advanced bladder cancer and for patients who cannot tolerate or have failed chemotherapy.
  • Trimodal therapy — combining chemotherapy, radiation, and sometimes immunotherapy — offers a bladder-preserving option for muscle-invasive cancer in selected patients.
  • For early-stage non-muscle-invasive cancer, BCG remains the standard, but combination approaches and newer intravesical drugs are being studied to improve outcomes.
  • Genetic testing of the tumor is becoming routine, as certain mutations predict which immunotherapy drugs will work best.

How immunotherapy changed advanced bladder cancer treatment

Until about 2016, chemotherapy was the only systemic option for advanced bladder cancer. Patients received cisplatin-based regimens, which worked for some but caused severe side effects and had limited durability. The approval of atezolizumab by the FDA in 2016 for platinum-ineligible patients marked a turning point. Since then, nivolumab and pembrolizumab have also been approved, and these drugs are now used earlier in treatment — not just as a last resort.

Checkpoint inhibitors work by blocking proteins that cancer cells use to hide from the immune system. In bladder cancer, response rates vary widely depending on tumor characteristics. Patients whose tumors have high levels of PD-L1 (a protein on cancer cell surfaces) tend to respond better, which is why testing for PD-L1 expression is now routine. Some patients see their tumors shrink significantly and maintain that response for years; others see no benefit. This unpredictability is why genetic profiling of the tumor — looking at PD-L1 status, microsatellite instability, and tumor mutational burden — has become standard practice to guide treatment choice.

Trimodal therapy as an alternative to bladder removal

Radical cystectomy has been the standard treatment for muscle-invasive bladder cancer for decades, but it means permanent loss of bladder function and requires either a surgically created pouch or external collection system. Trimodal therapy offers an alternative for patients who want to keep their bladder and are willing to undergo intensive treatment and close follow-up.

The approach combines maximal transurethral resection of the bladder tumor (TURBT), concurrent chemotherapy (usually cisplatin), and external beam radiation therapy. Some centers add a checkpoint inhibitor after radiation. Studies comparing trimodal therapy to cystectomy show similar five-year survival rates in carefully selected patients — typically those with solitary tumors, no carcinoma in situ (CIS), and good kidney function. However, trimodal therapy requires strict patient selection and close surveillance with cystoscopy and imaging every three months for the first two years. If the cancer recurs or persists, cystectomy becomes necessary.

Updates to early-stage bladder cancer treatment

Non-muscle-invasive bladder cancer (NMIBC) — tumors confined to the inner lining or lamina propria — accounts for about 75 percent of new diagnoses. BCG remains the gold standard intravesical therapy (medication placed directly in the bladder) for high-risk disease after TURBT. However, BCG shortages have been chronic, and not all patients respond or tolerate it well.

Recent research has explored combination approaches to improve BCG outcomes. Studies of BCG plus interferon-alpha showed better recurrence-free survival than BCG alone in some patient groups, though the benefit is modest and not universal. Newer intravesical agents like gemcitabine, mitomycin C, and combination regimens are being tested as alternatives or additions to BCG. Additionally, nadofaragene firadenovec (a gene therapy delivered into the bladder) was approved by the FDA in 2023 for BCG-unresponsive non-muscle-invasive cancer, offering a new option for patients who fail or cannot tolerate BCG.

Genetic testing and personalized treatment selection

Tumor profiling has become routine in bladder cancer care, particularly for advanced disease. Testing typically looks for PD-L1 expression, microsatellite instability (MSI), and tumor mutational burden (TMB). These markers help predict which patients will benefit from immunotherapy and which may need chemotherapy instead.

Some centers also test for specific mutations — such as in FGFR3, ERBB2, or TP53 — that may predict response to targeted drugs. For example, erdafitinib, an FGFR inhibitor, was approved in 2019 for advanced urothelial cancer with FGFR mutations. While targeted therapy is not yet standard for all patients, it represents a growing area of precision medicine in bladder cancer. Discussing tumor profiling results with your oncologist can help clarify which treatment options are most likely to work for your specific cancer.

Clinical trials and emerging treatments

Several promising approaches are in active development. Combination immunotherapy — using two checkpoint inhibitors together — is being studied to see if it improves response rates compared to single-agent therapy. Other trials are exploring immunotherapy combined with chemotherapy or radiation, or combined with targeted drugs that block specific mutations.

Antibody-drug conjugates (ADCs) are another emerging class. These drugs attach chemotherapy directly to antibodies that target cancer cells, potentially delivering higher doses to tumors while sparing healthy tissue. Enfortumab vedotin, an ADC targeting Nectin-4, was approved in 2019 and is now used in advanced disease. Newer ADCs are in clinical trials. If you have advanced bladder cancer or have failed standard treatments, asking your oncologist about clinical trials may open access to these newer approaches before they become widely available.

What happens after treatment: surveillance and recurrence

Bladder cancer has a high recurrence rate, especially for early-stage disease. After TURBT and intravesical therapy, surveillance typically includes cystoscopy every three months for the first year, then every six months for the second year, then annually. For patients treated with trimodal therapy, surveillance is more intensive in the first two years.

For advanced disease treated with immunotherapy, imaging (CT or MRI) is usually done every 8 to 12 weeks initially to assess response. If the cancer recurs after immunotherapy, options depend on prior treatments and overall health. Some patients may be candidates for chemotherapy, targeted therapy, or clinical trials. Others may proceed to cystectomy if they have not had surgery. Your oncologist will discuss the best path based on your specific situation and what you have already received.

Frequently Asked Questions

Is immunotherapy better than chemotherapy for bladder cancer?

Not universally. Immunotherapy works well for some patients and not at all for others, depending on tumor characteristics like PD-L1 status. For fit patients with advanced disease, immunotherapy is often tried first because it typically has fewer side effects than chemotherapy. However, chemotherapy remains standard for some situations, and some patients benefit from both.

Can I keep my bladder if I have muscle-invasive cancer?

Trimodal therapy (chemotherapy, radiation, and TURBT) offers a bladder-sparing option for selected patients with muscle-invasive disease. Success depends on tumor size, location, and your ability to tolerate intensive treatment and close follow-up. Discuss with your oncologist whether you are a candidate.

What does it mean if my tumor has high PD-L1?

High PD-L1 expression suggests your immune system may respond well to checkpoint inhibitor immunotherapy. However, some patients with low PD-L1 also respond, and some with high PD-L1 do not. PD-L1 status is one factor among several that guide treatment choice, not a may provide of outcome.

How often do I need cystoscopy after treatment?

For early-stage disease treated with TURBT and BCG, cystoscopy is typically done every three months for the first year, then every six months for the second year, then annually. For muscle-invasive disease treated with trimodal therapy, surveillance is more frequent in the first two years. Your oncologist will set a schedule based on your specific cancer and treatment.

Are there treatments for BCG-resistant bladder cancer?

Yes. Nadofaragene firadenovec (a gene therapy) was approved in 2023 for BCG-unresponsive non-muscle-invasive cancer. Checkpoint inhibitors are also being studied. If BCG fails, discuss with your urologist whether you are a candidate for these newer options or whether cystectomy is recommended.